dosimetry of beryllium in an animal model by accelerator mass spectrometry (ams) marina...
TRANSCRIPT
Dosimetry of Beryllium in an Animal Model Dosimetry of Beryllium in an Animal Model by Accelerator Mass Spectrometry (AMS)by Accelerator Mass Spectrometry (AMS)
Marina Chiarappa-Zucca
R.C. Finkel
J.E. McAninch
R.E. Martinelli
K.W. Turteltaub
Lawrence Livermore National Laboratory University of California
Our aim is to develop a method to quantify attomole Our aim is to develop a method to quantify attomole (10(10-18-18) amounts of Be in biological samples) amounts of Be in biological samples
• This method should enable the identification of molecular targets of Be at very low doses and provide detailed characterization of Be dosimetry
• Demonstration of this capability will facilitate research collaborations on the cellular and molecular mechanisms of CBD
OutlineOutline
• Introduction– What is accelerator mass spectrometry (AMS)?
• Experimental Approach– Sample preparation steps for extracting Be for AMS – AMS measurement of Be standards– Data from experiments showing Be distribution in
mouse tissues
• Conclusions
AMS counts nuclei directly rather then measuring radioactive decay
This results in 3-9 orders of magnitude more sensitivity relative to scintillation counting
Allows analysis of attomole quantities in small samples (µg-mg) with low activity levels (nCi-fCi)
LLNL has 15 years of experience with AMS and has pioneered the bioscience applications
AMS provides high sensitivity measurements AMS provides high sensitivity measurements of long-lived (10 < tof long-lived (10 < t1/2 1/2 > 10> 107 7 yrs) radioisotopesyrs) radioisotopes
Current AMS Capability
Developing Capability
Long-lived isotopes with possible applications using AMS10 yrs < t1/2 < 107 yrs
Difficult to produceFission fragments
Ce Tb Dy Ho Er Tm Yb LuLa Pr Nd Pm Sm Eu Gd
Ac Th UPa Np Pu Am Cm Bk Cf Es Fm Md No Lr
Pd
NaMg Al
Ga
In
Tl
B
As
Sb
Bi
N
P
Se
Te
O
S
Po
C
Ge
Pb
Sn
Si
He
Ne
Ar
Kr
Xe
Rn
Cl
Br
F
At
I
NiSc V Cr Co Cu Zn
Y Ru Rh Ag Cd
Ta W Os Ir Au
Ti MnFe
Zr Nb Tc
Hf Re Pt Hg
Mo
Ca
Be
H
Li
K
Rb
Fr
Ba
Ra
Cs
Sr
Accelerators at Lawrence Livermore National Accelerators at Lawrence Livermore National LaboratoryLaboratory
64 samples (plus standards and blanks) measured as a set
>100 unknowns can be quantified in 24 hr of accelerator time
14C BioAMS
Tandem; multiple isotopes including 10Be
10Be has significant advantages compared to other Be isotopes
Routine sensitivity is ~0.02 fg
Experiments require fCi total activities
10Be has a long half life (1.6 My) and therefore can be measured in samples from months to years
10Be in low dose experiments can typically be handled as non-radioactive and non-hazardous
AMS can be used to measure AMS can be used to measure 1010BeBe
There are multiple steps for extracting Be from There are multiple steps for extracting Be from samples for AMS measurementsamples for AMS measurement
AMS Ion SourcePacking intoAMS target
Oxidizing to BeO
DisposableQuartz Crucibles
PrecipitationAcid digestion
Each data point represents the mean ± SD of three independently prepared standards
Instrument precision is 1-3%
AMS measurement of standards is linear in AMS measurement of standards is linear in the range of interest with good precision the range of interest with good precision
1.0E+05
1.0E+07
1.0E+09
1.00E+05 1.00E+07 1.00E+09
Expected 10Be atoms
Method Detection Limit
109
107
105
Mea
sure
d 10
Be
ato
ms
107 109
30 g male ICR mice
Intraperitoneal injection of 0.05, 0.5, and 5.0 µg Be (~2-200 µg/kg body weight)
Three mice used for each dose
24 hr exposure
Liver, spleen, kidneys, lung, blood, and femurs prepared for AMS analysis
Proof of concept experiments show Be Proof of concept experiments show Be distribution in mouse tissuesdistribution in mouse tissues
Be measured in tissues is dose-dependent Be measured in tissues is dose-dependent within dose range studiedwithin dose range studied
1.0E-03
1.0E-01
1.0E+01
1.0E+03
1.0E+05
1.E-04 1.E-02 1.E+00
FemurSpleenLiver BloodLungKidney
105
10-3
10
0.001 0.1 10
Be
(ng
/g w
et t
issu
e)
Total Dose (µg Be)
method detection limit
* **
Spleen and blood data extrapolated to determine dose limits with current MDL
~ 200 pg (.007 µg/kg bw) * ~ 0.01 µg (0.3 µg/kg bw) **
These doses are below environmental Be exposures (e.g. for humans 0.9 0.5 µg/kg bw)
ConclusionsConclusions
• AMS provides high sensitivity 10Be measurements in biological samples
• Our future direction is to study mechanisms of Be disease– Explore molecular dosimetry– Identify molecular (e.g. protein) targets that are
responsible or involved in CBD– Evaluate the correlation between these endpoints
and susceptibility to CBD
• We are ready now to collaborate with other researchers that have specific applications for this capability